60
Participants
Start Date
August 31, 2011
Primary Completion Date
June 30, 2015
Study Completion Date
August 31, 2015
RSV MEDI ΔM2-2 vaccine
Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
Placebo vaccine
Given intranasally once at a baseline study visit
John Hopkins Center for Immunization Research, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)
NIH